login
login
Image header Agence Europe
Europe Daily Bulletin No. 12743
Contents Publication in full By article 13 / 31
EU RESPONSE TO COVID-19 / Health

Interim analysis casts doubt on efficacy of Covid-19 vaccine developed by CureVac

The EU may still have to wait to receive the hundreds of millions of doses of Covid-19 vaccine ordered from the German laboratory CureVac. On the evening of Wednesday 16 June, the company published inconclusive interim results on the effectiveness of its first-generation vaccine candidate (CVnCoV).

In the unprecedented context of at least 13 variants circulating within the study population subset assessed at this interim analysis, CVnCoV demonstrated an interim vaccine efficacy of 47%...

Contents

BEACONS
SECTORAL POLICIES
ECONOMY - FINANCE - BUSINESS
EU RESPONSE TO COVID-19
EXTERNAL ACTION
SECURITY - DEFENCE
COURT OF JUSTICE OF THE EU
FUNDAMENTAL RIGHTS - SOCIETAL ISSUES
COUNCIL OF EUROPE
NEWS BRIEFS
CORRIGENDUM